ACHIEVE LIFE SCIENCES INC. - COMMON SHARES

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

25 Jan 2022 08:00:04 By Nasdaq GlobeNewswire

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

06 Jan 2022 08:30:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

04 Jan 2022 08:30:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development

22 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation

23 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

22 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

09 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Participation in November Investor Conferences

04 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation

02 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021

26 Oct 2021 08:30:00 By Nasdaq GlobeNewswire